In a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Evaluating combination CAR-T cell therapy for recurrent or treatment-resistant multiple myeloma
In a nutshell This study evaluated the safety and effectiveness of combining two T-cell therapies for multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that this treatment showed promising effectiveness for these patients. Some background Treatment for patients with MM that has come back (relapsed)...
Read MoreIs camrelizumab effective for recurring or resistant classical Hodgkin’s lymphoma?
In a nutshell This study evaluated camrelizumab (SHR 1210) for patients with classical Hodgkin's Lymphoma (cHL) that has come back or is resisting treatment. The authors concluded that this drug is a safe and effective treatment for these patients. Some background After initial treatment, 5-10% of patients with cHL do not...
Read MoreLooking for patients with relapsed or unresponsive multiple myeloma to try allogeneic CAR-T cell therapy
In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...
Read MoreSearching for patients with relapsed/unresponsive non-Hodgkin lymphoma to test an experimental antibody drug
In a nutshell This study is examining the effects of IGM-2323 for certain types of relapsed/unresponsive non-Hodgkin lymphoma. The main outcomes that will be measured are the side effects experienced by patients and the effectiveness of treatment. This trial is recruiting in the United States. The details Non-Hodgkin lymphoma (NHL) is a...
Read MoreInotuzumab ozogamicin treatment for patients with acute lymphoblastic leukemia and the burden of hospitalization
In a nutshell This study aimed to investigate if treatment with inotuzumab ozogamicin in patients with relapsed/unresponsive acute lymphoblastic leukemia was associated with lower healthcare system burden compared to standard of care. This study...
Read MoreNivolumab in previously treated advanced non-small cell lung cancer – what is the long-term outlook for survival?
In a nutshell This study investigated survival rates in advanced non-small cell lung cancer (NSCLC) after nivolumab (Opdivo) treatment. They found that nivolumab was associated with longer survival time in patients that responded to treatment. Some background Lung cancer (LC) is one of the most common cancers worldwide. Non-small...
Read MoreEvaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia
In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...
Read MoreEvaluating Kd and Vd chemotherapy for patients with relapsed or refractory multiple myeloma
In a nutshell This study compared the effectiveness of Kd (carfilzomib, dexamethasone) chemotherapy to Vd (bortezomib, dexamethasone) chemotherapy in patients with multiple myeloma (MM). This study found that Kd improved survival outcomes and had fewer side effects compared to Vd chemotherapy for these patients. Some background Multiple...
Read MoreLooking for patients with relapsed or unresponsive multiple myeloma to test a new antibody drug
In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment. The details Both multiple myeloma (MM) and non-Hodkin lymphoma...
Read MoreEvaluating BCD chemotherapy for patients with peripheral T-cell lymphoma
In a nutshell This study evaluated the safety and effectiveness of BCD chemotherapy (bendamustine, carboplatin, and dexamethasone) for patients with peripheral T-cell lymphoma that has come back or stopped responding to treatment. This study concluded that this treatment was promising, with minimal side effects. Some background Peripheral T-cell...
Read MoreVenetoclax in patients with acute myeloid leukemia where hypomethylating agents have failed
In a nutshell This study aimed to investigate if venetoclax would enable patients with acute myeloid leukemia to overcome disease progression after hypomethylating agents. This study concluded that adding venetoclax to these patient's treatment may result in a substantial...
Read More